載入...
Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress‐Regulated Protein Translation
PTC299 is a novel small molecule that specifically blocks the production of protein from selected mRNAs that under certain conditions use noncanonical ribosomal translational pathways. Hypoxia, oncogenic transformation, and viral infections limit normal translation and turn on these noncanonical tra...
Na minha lista:
| 發表在: | Clin Pharmacol Drug Dev |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley and Sons Inc.
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5066743/ https://ncbi.nlm.nih.gov/pubmed/27310330 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.240 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|